GNFT
Genfit S.A.·Healthcare
8.95
4.070%(+0.35)
Close PriceLast Updated: — ET
52W L: $2.5552W H: $10.00
GNFT NEWS
globenewswire.com
2d ago
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 25, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights its broad participation at EASL Congress 2026. This visibility reflects both its scientific momentum and its active involvement in the ACLF ecosystem, as well as its position at an inflection point in MASH, while also highlighting the continuous progress made in PBC, driven by its partner Ipsen.
globenewswire.com
6d ago
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); May 21, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its cash position as of March 31, 2026 and revenues for the first three months of 20261 and provides a corporate update.
globenewswire.com
May 11
GENFIT : Assemblée Générale Mixte du 15 juin 2026 — modalités de mise à disposition des documents préparatoires
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 11 mai 2026 - GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd'hui la publication dans l'édition du Bulletin des Annonces Légales Obligatoires (BALO) n° 56 du 11 mai 2026 de l'avis de réunion relatif à l'Assemblée Générale Mixte qui se déroulera le 15 juin 2026 à 10h00 (heure de Paris) dans les locaux de la Faculté de Pharmacie de Lille situés sur le Parc Eurasanté, 3 rue du Professeur Laguesse à Lille (59000), France.
globenewswire.com
May 11
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 11, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 11, 2026 French legal announcements bulletin n°56 (Bulletin des Annonces Légales Obligatoires - BALO) the notice of the Combined Shareholders Meeting, which will be held on June 15, 2026, at 10:00 am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
globenewswire.com
May 11
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 11, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 11, 2026 French legal announcements bulletin n°56 (Bulletin des Annonces Légales Obligatoires - BALO) the notice of the Combined Shareholders Meeting, which will be held on June 15, 2026, at 10:00 am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France. All documentation regarding this Combined Shareholders' Meeting will be available to shareholders in accordance with existing regulations on the Company's website, in the Financials section under the Combined Shareholders Meeting tab (https://ir.genfit.com/financial-information/shareholders-meeting).
globenewswire.com
Apr 20
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 20, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the publication of its 2026 extra-financial performance report (fiscal year 2025), available on its website.
